EA202191107A1 - T-клеточные рецепторы ny-eso-1 и способы их применения - Google Patents
T-клеточные рецепторы ny-eso-1 и способы их примененияInfo
- Publication number
- EA202191107A1 EA202191107A1 EA202191107A EA202191107A EA202191107A1 EA 202191107 A1 EA202191107 A1 EA 202191107A1 EA 202191107 A EA202191107 A EA 202191107A EA 202191107 A EA202191107 A EA 202191107A EA 202191107 A1 EA202191107 A1 EA 202191107A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- eso
- cell receptors
- methods
- application
- tcrs
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 title abstract 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749194P | 2018-10-23 | 2018-10-23 | |
| PCT/US2019/057543 WO2020086647A1 (en) | 2018-10-23 | 2019-10-23 | Ny-eso-1 t cell receptors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191107A1 true EA202191107A1 (ru) | 2021-09-17 |
Family
ID=68582342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191107A EA202191107A1 (ru) | 2018-10-23 | 2019-10-23 | T-клеточные рецепторы ny-eso-1 и способы их применения |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12466870B2 (enExample) |
| EP (1) | EP3870602A1 (enExample) |
| JP (1) | JP7569313B2 (enExample) |
| KR (1) | KR102933479B1 (enExample) |
| CN (1) | CN113454110B (enExample) |
| AU (2) | AU2019364367B2 (enExample) |
| CA (1) | CA3117539A1 (enExample) |
| EA (1) | EA202191107A1 (enExample) |
| MA (1) | MA53981A (enExample) |
| WO (1) | WO2020086647A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3551221T2 (ro) | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| CN113454110B (zh) | 2018-10-23 | 2024-07-02 | 里珍纳龙药品有限公司 | Ny-eso-1 t细胞受体和其使用方法 |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| AU2021297458B2 (en) * | 2020-06-25 | 2026-06-18 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP7526079B2 (ja) * | 2020-11-13 | 2024-07-31 | Ykk Ap株式会社 | 樹脂枠の製造方法、樹脂枠 |
| TW202246511A (zh) * | 2021-02-25 | 2022-12-01 | 美商萊爾免疫藥物股份有限公司 | 靶向ny-eso-1之增強免疫細胞療法 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CN113912701B (zh) * | 2021-10-14 | 2024-07-19 | 深圳大学总医院 | Tcr及其在诊断/治疗中的应用 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2023114433A1 (en) * | 2021-12-15 | 2023-06-22 | 3T Biosciences, Inc. | Methods and systems for assessing immune cell receptors and antigens |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US12584107B2 (en) | 2022-01-20 | 2026-03-24 | 3T Biosciences, Inc. | T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells |
| US20230287448A1 (en) * | 2022-01-20 | 2023-09-14 | 3T Biosciences, Inc. | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａｓ調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| HK1008049A1 (en) | 1987-09-11 | 1999-04-30 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and use therefor |
| ATE110108T1 (de) | 1987-12-11 | 1994-09-15 | Whitehead Biomedical Inst | Genetische modifizierung von endothelialen zellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
| NZ507886A (en) | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| WO2005113595A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2835200T3 (es) * | 2012-05-22 | 2021-06-22 | Us Health | Uso médico de células que comprenden receptores de células T anti-NY-ESO-1 |
| DK2971045T3 (da) | 2013-03-13 | 2019-09-16 | Health Research Inc | Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen |
| JP6549564B2 (ja) * | 2013-06-26 | 2019-07-24 | グアンドン シャンスエ ライフ サイエンス， リミテッド． | 高安定性のｔ細胞受容体およびその製法と使用 |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| CN105985427A (zh) * | 2015-02-06 | 2016-10-05 | 广州市香雪制药股份有限公司 | 高亲和力ny-eso t细胞受体 |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| CN106188275A (zh) * | 2015-05-06 | 2016-12-07 | 广州市香雪制药股份有限公司 | 识别ny-eso-1抗原短肽的t细胞受体 |
| KR20180043800A (ko) * | 2015-09-09 | 2018-04-30 | 이뮨 디자인 코포레이션 | Ny-eso-1 특이적 tcrs 및 그의 사용 방법 |
| CN106432475B (zh) * | 2015-10-19 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 高亲和力ny-eso t细胞受体 |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| AU2018207172B2 (en) * | 2017-01-13 | 2023-10-12 | Mink Therapeutics, Inc. | T cell receptors that bind to NY-ESO-1 and methods of use thereof |
| CN108456247A (zh) * | 2017-02-20 | 2018-08-28 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的t细胞受体及其用途 |
| CN113454110B (zh) | 2018-10-23 | 2024-07-02 | 里珍纳龙药品有限公司 | Ny-eso-1 t细胞受体和其使用方法 |
-
2019
- 2019-10-23 CN CN201980085431.3A patent/CN113454110B/zh active Active
- 2019-10-23 KR KR1020217015373A patent/KR102933479B1/ko active Active
- 2019-10-23 JP JP2021522096A patent/JP7569313B2/ja active Active
- 2019-10-23 CA CA3117539A patent/CA3117539A1/en active Pending
- 2019-10-23 EP EP19804919.9A patent/EP3870602A1/en active Pending
- 2019-10-23 WO PCT/US2019/057543 patent/WO2020086647A1/en not_active Ceased
- 2019-10-23 EA EA202191107A patent/EA202191107A1/ru unknown
- 2019-10-23 US US17/287,643 patent/US12466870B2/en active Active
- 2019-10-23 MA MA053981A patent/MA53981A/fr unknown
- 2019-10-23 AU AU2019364367A patent/AU2019364367B2/en active Active
-
2025
- 2025-05-23 AU AU2025203827A patent/AU2025203827A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210403527A1 (en) | 2021-12-30 |
| MA53981A (fr) | 2021-09-01 |
| WO2020086647A8 (en) | 2020-05-28 |
| WO2020086647A1 (en) | 2020-04-30 |
| US12466870B2 (en) | 2025-11-11 |
| CN113454110A (zh) | 2021-09-28 |
| AU2019364367A1 (en) | 2021-05-27 |
| KR102933479B1 (ko) | 2026-03-04 |
| JP7569313B2 (ja) | 2024-10-17 |
| AU2019364367B2 (en) | 2025-02-27 |
| AU2025203827A1 (en) | 2025-06-12 |
| JP2022505679A (ja) | 2022-01-14 |
| CA3117539A1 (en) | 2020-04-30 |
| KR20210093908A (ko) | 2021-07-28 |
| CN113454110B (zh) | 2024-07-02 |
| EP3870602A1 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020086647A8 (en) | Ny-eso-1 t cell receptors and methods of use thereof | |
| BR112021025548A2 (pt) | Receptores de células t mage-a4 e métodos de uso dos mesmos | |
| CY1125508T1 (el) | Υποδοχεις τ-κυτταρων ειδικων για το συμπλοκο καρκινικου αντιγονου ny-eso-1-hla-a 02 | |
| EA201991696A1 (ru) | Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения | |
| EA202092436A1 (ru) | Противораковые соединения, нацеливающие на ядерные гормональные рецепторы | |
| EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
| CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
| EA202192327A1 (ru) | T-клеточные рецепторы, специфичные к mage-a4 | |
| MX2021004270A (es) | Anticuerpos estabilizadores de trem2. | |
| EA202092032A1 (ru) | Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| CY1121962T1 (el) | Υποδοχεις τ κυτταρου | |
| CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
| CO2019010524A2 (es) | Plataforma de identificación de péptidos inmunogénicos basada en población | |
| BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
| AR115963A1 (es) | Anticuerpos anti-il1rap y métodos de uso de estos | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
| EA201992610A1 (ru) | Экспансия -t-клеток, композиции и способы их применения | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| EA201691078A1 (ru) | Терапевтические пептиды | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| BR112022014461A2 (pt) | Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение |